Search

Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System Against Infectious Diseases

Standing together in support of improved access to obesity care

Learn more about how we’re supporting The Obesity Society and their recent consensus statement on obesity to help raise awareness and improve access to care for people living with this chronic medical condition.

Boehringer Ingelheim, Fashion Institute of Technology’s DTech Lab introduce fifth piece to award-winning design collection that raises awareness of rare disease

J-Code Issued for SPEVIGO

Boehringer Ingelheim receives permanent J-code for SPEVIGO, indicated for the treatment of generalized pustular psoriasis flares in adults

FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim’s Basaglar™ (insulin glargine injection)

Actress Angela Bassett joins For Your SweetHeart™ to urge people with diabetes to know their heart disease risk — in honor of her mom

Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders

Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases

Boehringer included on LinkedIn’s “Top Companies 2024” list

Investing in our people is at the core of what we do

Interview with Norbert Kraut: How cancer drives us forward

Norbert Kraut, our Global Head of Cancer Research at Boehringer Ingelheim, shares our approach to advancing cancer research and exploring new technologies

Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*star for Targeted Cancer Therapies

Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19

Supporting People with Diabetes and Related Conditions in the Time of COVID-19

Helping pets in hurricane-ravaged Puerto Rico

Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies

SEMINTRA® (Telmisartan Oral Solution) | Boehringer Ingelheim US

Introducing SEMINTRA® (telmisartan oral solution) —The first FDA-approved liquid solution for the control of systemic feline hypertension.

Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists

Yew Looi Liew Named President of U.S. Human Pharma for Boehringer Ingelheim Pharmaceuticals, Inc.

Health disparities in Black and African Americans

Addressing social determinants of health in cardio-kidney-metabolic care

Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics For Geographic Atrophy, a Leading Cause of Blindness Worldwide

Exploring T-cells in cancer

Lamine Mbow, our Global Head of Cancer Immunology and Immune Modulation, shares our approach to immuno-oncology, highlighting our investigational T-cell engagers platform and how we are driving innovation to potentially deliver meaningful advances to peop

Boehringer Ingelheim Launches Groundbreaking Initiative “Cuida tu Don” with Entertainer “Don Francisco” Aimed at Hispanics with Type 2 Diabetes

Celebrating the power of people and their experiences: Observations for Hispanic/ Latinx Heritage Month

Our Boehringer colleagues share how their experiences with their culture have influenced their approach to life and work.

Boehringer Ingelheim Animal Health Appoints Randolph Legg to Lead U.S. Commercial Business

Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan Corporation

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers